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Background:  `-adrenergic receptor (`-AR) polymorphisms and `-blocker therapy are associated with increases in glucose and lipid levels. We 
hypothesized that common `1 and `2-AR single nucleotide polymorphisms (SNPs) are associated with metabolic and lipid variables in patients 
with hypertension, and would interact with B-blocker treatment assignment to affect these outcomes.
Methods:  In a double-blinded, randomized, multicenter clinical trial, non-diabetic, hypertensive individuals were assigned to receive carvedilol or 
metoprolol succinate. Blood was drawn at baseline, 3, and 6 months for fasting measurements of glucose, insulin, cholesterol, triglycerides (TG), low-
density and high-density lipoprotein cholesterol levels. Homeostasis model of insulin resistance (HOMA-IR) was calculated as glucose*insulin/405. 
Genotypes for `-AR SNPs Ser49Gly, Gly389Arg, Arg16Gly, & Gln27Glu were determined by Real Time PCR. Linear mixed models with SNP effect alone, 
with treatment, SNP/treatment interaction, age, body-mass index, race, ethnicity, and baseline diastolic and systolic blood pressure were used to 
examine associations between `-AR polymorphisms and outcomes and SNP interactions with `-blocker therapy (pint).
Results:  There were 322 subjects (148 females), mean age 51 (sd=11; range 22-80) years old. For carvedilol and metoprolol, mean changes in 
insulin were -1.5 vs. 3.07 μIU/mL (p=0.007) from baseline to 6 months. No significant changes were noted between treatment groups for other 
variables. In univariate mixed models, patients with the Glu27Glu genotype had significantly lower insulin levels compared with the Gln27Gln 
genotype (p=0.006). Both Arg16Gly and Gln27Glu SNPs were significantly associated with TG levels in multivariate mixed models (p=0.012, 
p=0.037). There was a borderline significant interaction between the Arg16Gly SNP and treatment assignment affecting TG levels (pint=0.058).
Conclusions:  Differential effects of `-blocker therapy on insulin and TG are influenced by `2-AR polymorphisms. The adverse metabolic effects 
associated with use of metoprolol succinate appear to involve `-adrenergic mechanisms and may be mediated by `2-AR polymorphisms.
